A Peptide in a Pill – Oral Semaglutide in the Management of Type 2 Diabetes
Raja Selvarajan,1,* Rashmi Subramanian2,* 1Department of Diabetes and Research Kaveri Healthcare, Bangalore, Karnataka, India; 2Department of Research and Development, Kaveri Healthcare, Bangalore, Karnataka, India*These authors contributed equally to this workCorrespondence:...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2023-06-01
|
| Series: | Diabetes, Metabolic Syndrome and Obesity |
| Subjects: | |
| Online Access: | https://www.dovepress.com/a-peptide-in-a-pill--oral-semaglutide-in-the-management-of-type-2-diab-peer-reviewed-fulltext-article-DMSO |
| _version_ | 1797789437284843520 |
|---|---|
| author | Selvarajan R Subramanian R |
| author_facet | Selvarajan R Subramanian R |
| author_sort | Selvarajan R |
| collection | DOAJ |
| description | Raja Selvarajan,1,* Rashmi Subramanian2,* 1Department of Diabetes and Research Kaveri Healthcare, Bangalore, Karnataka, India; 2Department of Research and Development, Kaveri Healthcare, Bangalore, Karnataka, India*These authors contributed equally to this workCorrespondence: Raja Selvarajan, Tel +91 9902561571, Email dr.raj23@gmail.comAbstract: T2DM (type 2 diabetes mellitus) is a chronic and progressive illness with high morbidity and death rates. Oral semaglutide (Rybelsus®) is a combination of semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), and sodium N- (8- [2-hydroxybenzoyl] amino) caprylate (SNAC), an absorption enhancer that facilitates semaglutide absorption across the gastric epithelium in a concentration-dependent manner. This family of drugs apart from glucose lowering effects causes significant weight loss with lower risk of hypoglycemia, and some of them have been linked to a significant reduced major adverse cardiovascular events. GLP-1 RAs may assist persons with T2DM and chronic kidney disease (CKD), a major microvascular consequence of T2DM, in ways other than lowering blood sugar. Several large clinical studies, the bulk of which are cardiovascular outcome trials, show that GLP-1 RA treatment is safe and tolerated for persons with T2DM and impaired renal function and that it may potentially have renoprotective characteristics. This article focuses on the advances of oral GLP1-RA and describes the key milestones and predicted advantages.Keywords: type 2 diabetes mellitus, incretin system, GLP-1 receptor agonist, oral semaglutide, pioneer trials |
| first_indexed | 2024-03-13T01:49:39Z |
| format | Article |
| id | doaj.art-77a6850388434661a0048aa3df3a1031 |
| institution | Directory Open Access Journal |
| issn | 1178-7007 |
| language | English |
| last_indexed | 2024-03-13T01:49:39Z |
| publishDate | 2023-06-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Diabetes, Metabolic Syndrome and Obesity |
| spelling | doaj.art-77a6850388434661a0048aa3df3a10312023-07-02T19:49:17ZengDove Medical PressDiabetes, Metabolic Syndrome and Obesity1178-70072023-06-01Volume 161709172084302A Peptide in a Pill – Oral Semaglutide in the Management of Type 2 DiabetesSelvarajan RSubramanian RRaja Selvarajan,1,* Rashmi Subramanian2,* 1Department of Diabetes and Research Kaveri Healthcare, Bangalore, Karnataka, India; 2Department of Research and Development, Kaveri Healthcare, Bangalore, Karnataka, India*These authors contributed equally to this workCorrespondence: Raja Selvarajan, Tel +91 9902561571, Email dr.raj23@gmail.comAbstract: T2DM (type 2 diabetes mellitus) is a chronic and progressive illness with high morbidity and death rates. Oral semaglutide (Rybelsus®) is a combination of semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), and sodium N- (8- [2-hydroxybenzoyl] amino) caprylate (SNAC), an absorption enhancer that facilitates semaglutide absorption across the gastric epithelium in a concentration-dependent manner. This family of drugs apart from glucose lowering effects causes significant weight loss with lower risk of hypoglycemia, and some of them have been linked to a significant reduced major adverse cardiovascular events. GLP-1 RAs may assist persons with T2DM and chronic kidney disease (CKD), a major microvascular consequence of T2DM, in ways other than lowering blood sugar. Several large clinical studies, the bulk of which are cardiovascular outcome trials, show that GLP-1 RA treatment is safe and tolerated for persons with T2DM and impaired renal function and that it may potentially have renoprotective characteristics. This article focuses on the advances of oral GLP1-RA and describes the key milestones and predicted advantages.Keywords: type 2 diabetes mellitus, incretin system, GLP-1 receptor agonist, oral semaglutide, pioneer trialshttps://www.dovepress.com/a-peptide-in-a-pill--oral-semaglutide-in-the-management-of-type-2-diab-peer-reviewed-fulltext-article-DMSOtype 2 diabetes mellitusincretin systemglp-1receptor agonistoral semaglutidepioneer trails. |
| spellingShingle | Selvarajan R Subramanian R A Peptide in a Pill – Oral Semaglutide in the Management of Type 2 Diabetes Diabetes, Metabolic Syndrome and Obesity type 2 diabetes mellitus incretin system glp-1receptor agonist oral semaglutide pioneer trails. |
| title | A Peptide in a Pill – Oral Semaglutide in the Management of Type 2 Diabetes |
| title_full | A Peptide in a Pill – Oral Semaglutide in the Management of Type 2 Diabetes |
| title_fullStr | A Peptide in a Pill – Oral Semaglutide in the Management of Type 2 Diabetes |
| title_full_unstemmed | A Peptide in a Pill – Oral Semaglutide in the Management of Type 2 Diabetes |
| title_short | A Peptide in a Pill – Oral Semaglutide in the Management of Type 2 Diabetes |
| title_sort | peptide in a pill ndash oral semaglutide in the management of type 2 diabetes |
| topic | type 2 diabetes mellitus incretin system glp-1receptor agonist oral semaglutide pioneer trails. |
| url | https://www.dovepress.com/a-peptide-in-a-pill--oral-semaglutide-in-the-management-of-type-2-diab-peer-reviewed-fulltext-article-DMSO |
| work_keys_str_mv | AT selvarajanr apeptideinapillndashoralsemaglutideinthemanagementoftype2diabetes AT subramanianr apeptideinapillndashoralsemaglutideinthemanagementoftype2diabetes AT selvarajanr peptideinapillndashoralsemaglutideinthemanagementoftype2diabetes AT subramanianr peptideinapillndashoralsemaglutideinthemanagementoftype2diabetes |